

Innovation all for the patients



Roche A member of the Roche group

## Galderma Presented Results from Phase 2b Study of Nemolizumab in Patients with Atopic Dermatitis at the 2019 AAD Annual Meeting Late-breaking Session

TOKYO, March 11, 2019 –[Chugai Pharmaceutical Co., Ltd.](#) (TOKYO: 4519) announced that [Galderma, Nestlé Skin Health's Medical Solutions Business](#) issued a press release regarding the presentation of the results from phase 2b study of nemolizumab (CIM331) in patients with atopic dermatitis (AD) at [the 2019 American Academy of Dermatology Annual Meeting](#) Late-breaking Session held from March 1-5, 2019.

Please refer to the link below for details of the press release issued on March 8, 2019:

Galderma Presented Final Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis at the 2019 American Academy of Dermatology Annual Meeting Late-Breaking Session

<https://www.nestleskinhealth.com/news/galderma-presented-final-results-phase-2b-study-nemolizumab-patients-moderate-severe-atopic>

- The study met the primary endpoint of a greater improvement in Eczema Area and Severity Index (EASI) scores from baseline compared with placebo. A 73% reduction in EASI score was observed at Week 24 with nemolizumab compared with 58% for placebo.
- Nemolizumab-treated subjects showed early statistically significant improvements in itching and sleep compared with placebo-treated subjects.
- Nemolizumab was associated with a rapid onset of action on AD symptoms.
- Nemolizumab was well-tolerated across all dose levels in this trial. The most common adverse events observed were nasopharyngitis and upper respiratory tract infection. Subjects with pre-existing asthma reported an increase in asthma related events; these events were mostly mild and were reversible under treatment.
- Galderma is preparing for the global phase 3 pivotal study in mid-2019.

[Note]

Press release issued on July 21, 2016:

Chugai and Galderma Announce Global License Agreement for Nemolizumab (CIM331), Novel Biologic for Skin Diseases

<https://www.chugai-pharm.co.jp/english/news/detail/20160721083000.html>

### About EASI

EASI (Eczema Area and Severity Index) is a tool to demonstrate severity of dermatitis with score from 0 to 72.

###